Abstract
Increasing evidence suggests that of minimal residual disease (MRD) in bone marrow (BM) is one of the most relevant independent prognostic factors in multiple myeloma (MM). Recently, EuroFlow consortium developed and validates the Next Generation Flow cytometry (NGF) approach to evaluate BM MRD in MM patients, at very low levels and, simultaneously is able to estimate the sample hemodilution. Here, we evaluated flow-MRD by NGF in MM patients after autologous stem cell transplantation (ASCT) and compared with conventional techniques for response criteria in serum.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
